Circulating Podocalyxin, Tumstatin/Col-IVα3 and Chitinase 1: New Culprits in Vitiligo Occurrence

Circulating Podocalyxin, Tumstatin/Col-IVα3 and Chitinase 1: New Culprits in Vitiligo Occurrence


  • Şule Gençoğlu Department of Dermatology, Gozde Academy Hospitals, Malatya, Turkey


vitiligo, inflammation, adhesion, angiogenesis, immunity


Introductionː The roles of anti-adhesive podocalyxin (PODXL), ant-angiogenetic tumstatin/Col-IVα3 and neuroinflammation and innate immunity modulator Chitinase 1 (CHIT-1) in the etiology of vitiligo have not been studied yet.

Objectives: This study was planned to detect changes in serum PODXL, tumstatin/Col-IVα3 and CHIT1 levels in vitiligo patients.

Methods: This case-controlled study was performed on a total of 50 patients, 25 with vitiligo and 25 healthy controls. Participants in the vitiligo and control groups were matched in pairs for age and sex. At least 8-10 hours of overnight fasting, venous blood samples were taken from the participants in both groups and serum levels of podocalyxin, tumstatin/Col-IVα3 and CHIT 1 levels were measured by sandwich enzyme immunoassay.

Results: In the classification made according to the vitiligo European Task Force evaluation criteria, 18 of 25 vitiligo patients were in the slowly progressive phase and 7 patients were in the active progressive phase. Serum podocalyxin levels increased significantly in the vitiligo group compared to the controls (7.03±2.09 ng/ml vs. 4.99±1.20 ng/ml, p<0.02). However, serum tumstatin levels in vitiligo patients showed a significantly lower course compared to controls (4.88±1.76 ng/ml vs. 6.05±2.19 ng/nl, p<0.03). Serum CHIT-1 levels of vitiligo patients (42.4±7.22 ng/ml) were found to be significantly higher than the serum levels of the control group (34.5±5.33 ng/ml) (p<0.01).

Conclusion: Increased podocalyxin and CHIT1 levels versus decreased tumstatin levels are new biomarkers that support the role of anti-adhesive, anti-angiogenic and neuroinflammatory pathways in the formation of vitiligo.


Taïeb A, Picardo M. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007;20:27–35.

Burns T, Breathnach S, Cox N, Griffiths C. Rook’s Textbook of Dermatology. Eight. Oxford: Blackwell Science. 2010. doi:10.1002/9781444317633.

Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020;236:571–92.

Picardo M, Dell’Anna ML, Ezzedine K, Hamzavi I, Harris JE, Parsad D et al. Vitiligo. Nat. Rev. Dis. Prim. 2015;1:15011.

Sandoval-Cruz M, García-Carrasco M, Sánchez-Porras R, Mendoza-Pinto C, Jiménez-Hernández M, Munguía-Realpozo P et al. Immunopathogenesis of vitiligo. Autoimmun. Rev. 2011;10:762–5.

Richmond JM, Frisoli ML, Harris JE. Innate immune mechanisms in vitiligo: danger from within. Curr. Opin. Immunol. 2013;25:676–82.

Attili V, Attili S. Segmental and generalized vitiligo: Both forms demonstrate inflammatory histopathological features and clinical mosaicism. Indian J. Dermatol. 2013;58:433.

Hamano Y, Kalluri R. Tumstatin, the NC1 domain of α3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem. Biophys. Res. Commun. 2005;333:292–8.

Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB et al. Distinct Antitumor Properties of a Type IV Collagen Domain Derived from Basement Membrane. J. Biol. Chem. 2000;275:21340–8.

Kerjaschki D, Sharkey DJ, Farquhar MG. Identification and characterization of podocalyxin--the major sialoprotein of the renal glomerular epithelial cell. J. Cell Biol. 1984;98:1591–6.

Doyonnas R, Kershaw DB, Duhme C, Merkens H, Chelliah S, Graf T et al. Anuria, Omphalocele, and Perinatal Lethality in Mice Lacking the Cd34-Related Protein Podocalyxin. J. Exp. Med. 2001;194:13–28.

Le Tran N, Wang Y, Nie G. Podocalyxin in Normal Tissue and Epithelial Cancer. Cancers (Basel). 2021;13:2863.

Boot RG, Blommaart EFC, Swart E, Ghauharali-van der Vlugt K, Bijl N, Moe C et al. Identification of a Novel Acidic Mammalian Chitinase Distinct from Chitotriosidase. J. Biol. Chem. 2001;276:6770–8.

Sutherland TE. Chitinase-like proteins as regulators of innate immunity and tissue repair: helpful lessons for asthma? Biochem. Soc. Trans. 2018;46:141–51.

Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CCE et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25:E1–13.

Katz EL, Harris JE. Translational Research in Vitiligo. Front. Immunol. 2021. doi:10.3389/fimmu.2021.624517.

Frisoli ML, Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu. Rev. Immunol. 2020;38:621–48.

Montilla AM, Gómez-García F, Gómez-Arias PJ, Gay-Mimbrera J, Hernández-Parada J, Isla-Tejera B et al. Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata. Dermatol. Ther. (Heidelb). 2019;9:655–83.

Gauthier Y, Cario-Andre M, Lepreux S, Pain C, Taieb A. Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo. Br. J. Dermatol. 2003;148:95–101.

Le Poole IC, Van Den Wijngaard RMGJ, Westerhof W, Das PK. Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. Br. J. Dermatol. 1997;137:171–8.

Bastonini E, Bellei B, Filoni A, Kovacs D, Iacovelli P, Picardo M. Involvement of non‐melanocytic skin cells in vitiligo. Exp. Dermatol. 2019;28:667–73.

Becatti M, Prignano F, Fiorillo C, Pescitelli L, Nassi P, Lotti T et al. The Involvement of Smac/DIABLO, p53, NF-kB, and MAPK Pathways in Apoptosis of Keratinocytes from Perilesional Vitiligo Skin: Protective Effects of Curcumin and Capsaicin. Antioxid. Redox Signal. 2010;13:1309–21.

Weinman EJ. New functions for the NHERF family of proteins. J. Clin. Invest. 2001;108:185–6.

Cipollone JA, Graves ML, Köbel M, Kalloger SE, Poon T, Gilks CB et al. The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. Clin. Exp. Metastasis. 2012;29:239–52.

Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR et al. Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis. Science (80-. ). 2002;295:140–3.

Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C et al. Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrin. Cancer Cell. 2003;3:589–601.

Wu C-S, Yu H-S, Chang H-R, Yu C-L, Yu C-L, Wu B-N. Cutaneous blood flow and adrenoceptor response increase in segmental-type vitiligo lesions. J. Dermatol. Sci. 2000;23:53–62.

Westerhof W, D?Ischia M. Vitiligo puzzle: the pieces fall in place. Pigment Cell Res. 2007:070806223111002-???

Sutherland TE, Maizels RM, Allen JE. Chitinases and chitinase-like proteins: potential therapeutic targets for the treatment of T-helper type 2 allergies. Clin. Exp. Allergy. 2009;39:943–55.

Pinteac R, Montalban X, Comabella M. Chitinases and chitinase-like proteins as biomarkers in neurologic disorders. Neurol. - Neuroimmunol. Neuroinflammation. 2021;8:e921.

Guan S-P, Mok Y-K, Koo K-N, Chu K-L, Wong WS. Chitinases: Biomarkers for Human Diseases. Protein Pept. Lett. 2009;16:490–8.

Seibold MA, Reese TA, Choudhry S, Salam MT, Beckman K, Eng C et al. Differential Enzymatic Activity of Common Haplotypic Versions of the Human Acidic Mammalian Chitinase Protein. J. Biol. Chem. 2009;284:19650–8.






Original Article

How to Cite

Circulating Podocalyxin, Tumstatin/Col-IVα3 and Chitinase 1: New Culprits in Vitiligo Occurrence. Dermatol Pract Concept [Internet]. 2024 Jan. 31 [cited 2024 Jul. 13];14(1):e2024095. Available from: